Stealth’s Elamipretide Gets US FDA Review, But Same Questions Linger

 
• By Derrick Gingery
  
conference room table
Elamipretide's NDA filing provides a seat at the table, but Stealth BioTherapeutics still has work to do, its CEO said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Product Reviews

More from Pink Sheet